The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
The US Food and Drug Administration (FDA) has early this week approved GSK's new antibiotic, Blujepa (gepotidacin), for the ...
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
The FDA approved gepotidacin for the treatment of uncomplicated UTIs in women and adolescent girls aged 12 years or older, ...
The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract ...
Gepotidacin is an oral ... and vulvovaginal candidiasis. “The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” said Tony Wood, Chief Scientific ...
This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...